Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)

Recruiting now · Not applicable

Conditions studied: Apathy, Apathy in Dementia

In brief

The goal of this trial is to learn whether home-based robotic interventions can reduce apathy in people with cognitive decline. Apathy means reduced motivation, interest, or initiative in daily life. It is a common and distressing symptom in people with mild cognitive impairment (MCI) or dementia and can strongly affect both participants and their caregivers. This study will compare two different robotic interventions with standard occupational therapy. Researchers want to understand if these new technologies can help people become more engaged, motivated, and involved in everyday activities, and whether they also reduce stress and improve quality of life for caregivers. The main questions this study aims to answer are: * Do robotic interventions reduce apathy more than standard occupational therapy? * Are these robotic interventions easy to use and acceptable for people with cognitive impairment? * Do these interventions reduce caregiver stress and improve caregiver quality of life? Participants will be adults over 40 years of age with a diagnosis of mild cognitive impairment or dementia caused by a neurodegenerative disease, such as Alzheimer's disease, frontotemporal dementia, or dementia with Lewy bodies. All participants must show clinically relevant apathy and have a family member or caregiver who can support them during the study and answer questionnaires. Participants will be randomly assigned to one of three groups: * A telepresence robot group, where participants interact at home with a therapist through a remotely controlled robot that delivers personalized cognitive stimulation. * A social robot group, where participants interact at home with a humanoid robot that holds personalized conversations on topics of interest. * A control group receiving home-based occupational therapy, which is the current standard care for behavioral symptoms. Each intervention lasts six weeks and takes place in the participant's home. The robotic interventions are designed to fit into daily routines and can be adapted to the participant's abilities and preferences. Occupational therapy sessions focus on meaningful activities, environmental adaptations, and caregiver support. Participants will complete assessments at three time points: before the intervention, at the end of the six-week intervention, and eight weeks after the intervention ends. These assessments include interviews, questionnaires, and simple tasks to measure apathy, emotional responses, social interaction, and quality of life. Caregivers will also complete questionnaires about stress and daily burden. Researchers will also collect information about how often and how participants interact with the robots, such as how long conversations last and how engaged participants appear. These data will help researchers understand how robotic interactions relate to changes in apathy and behavior. This study aims to provide evidence on whether robotic technologies can be safely and effectively used at home to support people with cognitive impairment and apathy. The results may help develop new non-drug treatments and improve care options for people living with dementia and their caregivers.

Key facts

Study ID: NCT07404410
Run by: Giovanna Zamboni
People needed: 75
Starts: 2026-04-28
Expected to finish: 2026-11-30
Last updated by the study team: 2026-05-05

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 40 years or older
Clinical diagnosis of a neurocognitive disorder, including: Mild cognitive impairment (MCI) or mild behavioral impairment (MBI), or Major neurocognitive disorder (dementia), due to Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, or other neurodegenerative diseases.
Presence of clinically relevant apathy, defined as a score greater than 2 on the apathy domain (G) of the Neuropsychiatric Inventory (NPI).
Preserved ability to understand and produce spoken and written language sufficient to participate in the intervention and assessments.
Absence of clinically significant agitation or aggressiveness, defined as a score lower than 2 on the agitation/aggression domain (C) of the NPI.
Adequate educational and occupational history sufficient to exclude intellectual disability.
Availability of a study partner (family member, friend, or caregiver) who: Knows the participant well, Has contact with the participant for at least 10 hours per week, Is able to complete questionnaires about the participant, Is able to read, understand, and speak Italian, and Provides independent informed consent for participation.
Ability and willingness of the participant (and study partner, when applicable) to provide informed consent.

You may not qualify if…

Refusal or withdrawal of informed consent by the participant or the study partner.
History or current evidence of neurological conditions other than the target neurodegenerative diseases that may affect cognitive function (e.g., major stroke, brain tumor, normal pressure hydrocephalus, traumatic brain injury).
History or current diagnosis of major psychiatric disorders that could interfere with study participation or assessments.
Presence of medical conditions that may significantly affect cognitive function (e.g., severe renal or hepatic failure, untreated obstructive sleep apnea, hypothyroidism, vitamin B12 deficiency).
Clinically significant agitation or aggressiveness, defined as a score of 2 or higher on the agitation/aggression domain (C) of the Neuropsychiatric Inventory (NPI).
Inability to understand or communicate in Italian sufficient to complete study procedures.
Absence of an eligible study partner or withdrawal of consent by the study partner.

Where it is running

IRCCS "S. Maria Nascente" — Milan, Italy, Italy (enrolling)
Azienda Ospedaliero Universitaria di Modena — Modena, Italy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.